WEST Search History

Hide Items | Restore | Clear | Cancel

DATE: Tuesday, April 24, 2007

Hide?	Set Name	Query	Hit Count
	DB=USPT; PLUR=YES; OP=ADJ		
☐	L3	L2 and neurotro$5	56
☐	L2	(alzheim$5 or neurodegenera$7 or dement$7) and (514/217$3.ccls. or 514/317.ccls.)	532
☐	L1	(alzheim$5 or neurodegenera$7 or demet$7) and (514/217$3.ccls. or 514/317.ccls.)	507

END OF SEARCH HISTORY

=> d l8
L8 HAS NO ANSWERS
L8 STR



NODE ATTRIBUTES:
DEFAULT MLEVEL IS ATOM
DEFAULT ECLEVEL IS LIMITED

GRAPH ATTRIBUTES:
RING(S) ARE ISOLATED OR EMBEDDED
NUMBER OF NODES IS 20

STEREO ATTRIBUTES: NONE

=> s l8 ful
FULL SEARCH INITIATED 07:36:33 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED - 36034 TO ITERATE

100.0% PROCESSED 36034 ITERATIONS 17 ANSWERS
SEARCH TIME: 00.00.01

L10 17 SEA SSS FUL L8

```
      (FILE 'HOME' ENTERED AT 07:29:37 ON 24 APR 2007)

      FILE 'REGISTRY' ENTERED AT 07:29:46 ON 24 APR 2007

      FILE 'CAPLUS' ENTERED AT 07:30:09 ON 24 APR 2007
L1             1 S US20040072821/PN
L2           ANALYZE L1 1 RN :      21 TERMS

      FILE 'REGISTRY' ENTERED AT 07:31:57 ON 24 APR 2007
L3            21 S L2
L4             9 S L3 AND PYRIDIN?
L5               STRUC
L6             0 S L5
L7             1 S L5 FUL
L8               STRUC
L9             1 S L8
L10           17 S L8 FUL

      FILE 'CAPLUS' ENTERED AT 07:36:54 ON 24 APR 2007
L11           48 S L10
L12           47 S L11 NOT L1

      FILE 'REGISTRY' ENTERED AT 07:39:31 ON 24 APR 2007
L13            3 S  318467-13-9 OR   318467-14-0  OR   318467-16-2

      FILE 'CAPLUS' ENTERED AT 07:40:49 ON 24 APR 2007
L14            1 S L13

      FILE 'REGISTRY' ENTERED AT 07:42:56 ON 24 APR 2007
L15            1 S   318467-16-2
L16            1 S  159997-95-2

      FILE 'CAPLUS' ENTERED AT 07:44:40 ON 24 APR 2007
L17            4 S L16
L18            1 S L15

      FILE 'REGISTRY' ENTERED AT 07:45:32 ON 24 APR 2007
L19            1 S  159997-94-1

      FILE 'CAPLUS' ENTERED AT 07:46:01 ON 24 APR 2007
L20           40 S L19
L21           36 S L20 NOT L17
L22            0 S L21 AND DT/P
L23           16 S L21 AND P/DT
```

=> d bib abs hitstr l17 1-4

L17 ANSWER 1 OF 4 CAPLUS COPYRIGHT 2007 ACS on STN
AN 1998:157415 CAPLUS
DN 128:205136
TI Preparation of acylated amino acid derivatives for multi-drug resistance therapies and immune suppression.
IN Armistead, David M.; Harding, Matthew W.; Saunders, Jeffrey O.; Boger, Joshua S.
PA Vertex Pharmaceuticals Inc., USA
SO U.S., 34 pp., Cont.-in-part of U.S. 5,620,971.
CODEN: USXXAM
DT Patent
LA English
FAN.CNT 4

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 5723459	A	19980303	US 1995-377315	19950124
	US 5620971	A	19970415	US 1994-217982	19940325
PRAI	US 1991-697785	B2	19910509		
	US 1992-881152	B2	19920511		
	US 1992-952299	B2	19920928		
	US 1993-127814	B2	19930928		
	US 1994-217982	A2	19940325		

OS MARPAT 128:205136
GI



I



III

AB The present invention relates to novel acylated amino acid esters I [A = CH2, O, NH, alkylimino; B, D = (un)substituted (hetero)aryl, alk(en)(yn)yl, cycloalk(en)ylalk(en)(yn)yl, (hetero)aralkyl, cis-C(Q):CHT; Q = H, alk(en)(yn)yl; T = (un)substituted (hetero)aryl, substituted cycloalkyl; L = H, U; M = O, CHU; U = H, alk(en)yl, cycloalk(en)ylalk(en)yl, (hetero)aralk(en)yl, (hetero)aryl; J = H, alkyl, CH2Ph; K = alkyl, CH2Ph, cyclohexylmethyl; or JK = atoms to form 5- to 7-membered, optionally O- or S-containing heterocycle; m = 0-3; various provisos], as well as pharmaceutical compns. comprising them, which possess a broad range of useful biol. activities. These compds. can maintain, increase, or restore sensitivity of cells to therapeutic or prophylactic agents. They can also suppress, modify, or significantly

reduce an immune response, including an autoimmune response in a mammal. This invention also relates to pharmaceutical compns. comprising these compds. The compds. and pharmaceutical compns. of this invention are particularly well-suited for treatment of multi-drug resistant cells, for prevention of the development of multi-drug resistance, for use in multi-drug resistant cancer therapy, and for prevention or treatment of graft rejection and various autoimmune diseases. Over 100 I are reported, including both single and mixed diastereomers. Thus, 3-PhOC6H4CH2OH underwent oxidation to the aldehyde and reaction with Ph(CH2)3MgBr to give the racemic alc. 3-PhOC6H4CH(OH)(CH2)3Ph (II). Esterification of II with (S)-N-[(3,4,5-trimethoxyphenyl)glyoxyl]pipecolic acid (preparation given) yielded ester III as a mixture of diastereomers. In a test for reversal of multi-drug-resistance by a line of L1210 cells, selected I gave up to 18-fold increase in the antiproliferative potency of doxorubicin.

IT 159997-95-2P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of acylated amino acid esters for multi-drug resistance therapies and immune suppression.)

RN 159997-95-2 CAPLUS

CN L-Proline, 1-[oxo(3,4,5-trimethoxyphenyl)acetyl]-, 4-(3-pyridinyl)-1-[3-(3-pyridinyl)propyl]butyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RE.CNT 29 THERE ARE 29 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L17 ANSWER 2 OF 4 CAPLUS COPYRIGHT 2007 ACS on STN

AN 1997:307496 CAPLUS

DN 126:272378

TI Methods and compositions for stimulating neurite growth using compounds with affinity for FKBP12 in combination with neurotrophic factors

IN Armistead, David M.

PA Vertex Pharmaceuticals Incorporated, USA

SO S. African, 54 pp.
CODEN: SFXXAB

DT Patent

LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	ZA 9604852	A	19960729	ZA 1996-4852	19960607
	US 6037370	A	20000314	US 1995-486004	19950608
	CA 2222430	A1	19961227	CA 1996-2222430	19960606
	WO 9641609	A2	19961227	WO 1996-US10123	19960606

W: AL, AM, AT, AU, AZ, BB, BG, BR, BY, CA, CH, CN, CZ, DE, DK, EE, ES, FI, GB, GE, HU, IL, IS, JP, KE, KG, KP, KR, KZ, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG

RW: KE, LS, MW, SD, SZ, UG, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR,

IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN

	AU 9661119	A	19970109	AU 1996-61119	19960606
	EP 831812	A2	19980401	EP 1996-918469	19960606
	EP 831812	B1	20051207		
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI				
	CN 1202104	A	19981216	CN 1996-195690	19960606
	BR 9609333	A	19991013	BR 1996-9333	19960606
	NZ 310339	A	20000327	NZ 1996-310339	19960606
	NZ 501709	A	20001027	NZ 1996-501709	19960606
	JP 2002502355	T	20020122	JP 1997-503275	19960606
	IL 122346	A	20020523	IL 1996-122346	19960606
	IL 136118	A	20021201	IL 1996-136118	19960606
	RU 2197240	C2	20030127	RU 1998-100456	19960606
	PL 185798	B1	20030731	PL 1996-328723	19960606
	AT 311875	T	20051215	AT 1996-918469	19960606
	EP 1666037	A2	20060607	EP 2005-26521	19960606
	EP 1666037	A3	20060621		
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI				
	ES 2255077	T3	20060616	ES 1996-918469	19960606
	US 6124328	A	20000926	US 1997-795956	19970228
	AU 2000043801	A	20000907	AU 2000-43801	20000703
	AU 757406	B2	20030220		
	US 6326387	B1	20011204	US 2000-616539	20000714
PRAI	US 1995-486004	A	19950608		
	AU 1996-61119	A3	19960606		
	EP 1996-918469	A3	19960606		
	IL 1996-122346	A3	19960606		
	NZ 1996-310339	A1	19960606		
	WO 1996-US10123	W	19960606		
	US 1997-795956	A3	19970228		

OS MARPAT 126:272378

AB A pharmaceutically acceptable composition is disclosed which comprises (a) a neurotrophic amount of a compound with affinity for FK-506-binding protein FKBP12 e.g. having the formula BAC(:O)CH(K)N(J)C(:O)C(:E)D [A = O, NH, N(C1-4 alkyl); B = H, C1-6 (branched) alkyl, C2-6 (branched) alkenyl, C5-7 cycloalkyl, etc.; D = U; E = O, CHU (if D = H, then E = CH-U; if E = O, then D is not H); U = H, O-(C1-4)-straight or branched alkyl, O-(C2-4)-straight or branched alkenyl, C1-6 (branched) alkyl, C2-6 (branched) alkenyl, (substituted) C5-7 cycloalkyl, (substituted) C5-7 cycloalkenyl, etc.; J = H, C1-2 alkyl; K = C1-4 (branched) alkyl, benzyl, cyclohexylmethyl, or J and K taken together form 5-7 membered heterocyclic ring which may contain O, S, SO, SO2; and the stereochem. at carbon to which K is bonded = R or S] and pharmaceutically acceptable derivs. thereof; (b) a neurotrophic factor; and (c) a pharmaceutically carrier. The neurotrophic factor may be e.g. nerve growth factor. The methodol. of the invention can be used to promote repair of neuronal damage caused by disease or phys. trauma.

IT 159997-95-2
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(compds. with affinity for FKBP12 in combination with neurotrophic factors for stimulating neurite growth)

RN 159997-95-2 CAPLUS

CN L-Proline, 1-[oxo(3,4,5-trimethoxyphenyl)acetyl]-, 4-(3-pyridinyl)-1-[3-(3-pyridinyl)propyl]butyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L17 ANSWER 3 OF 4 CAPLUS COPYRIGHT 2007 ACS on STN
AN 1997:276774 CAPLUS
DN 126:343875
TI Preparation of acylated amino acid derivatives for multi-drug resistance therapies and immune suppression.
IN Armistead, David M.; Saunders, Jeffrey O.; Boger, Joshua S.
PA Vertex Pharmaceuticals Incorporated, USA
SO U.S., 35 pp., Cont.-in-part of U.S. Ser. No. 881,152, abandoned.
CODEN: USXXAM
DT Patent
LA English
FAN.CNT 4

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 5620971	A	19970415	US 1994-217982	19940325
	US 5723459	A	19980303	US 1995-377315	19950124
PRAI	US 1991-697785	B2	19910509		
	US 1992-881152	B2	19920511		
	US 1992-952299	B2	19920928		
	US 1993-127814	B2	19930928		
	US 1994-217982	A2	19940325		

OS MARPAT 126:343875
GI



I



III

AB The present invention relates to novel acylated amino acid esters I [A = CH2, O, NH, alkylimino; B, D = (un)substituted (hetero)aryl,

alk(en)(yn)yl, cycloalk(en)ylalk(en)(yn)yl, (hetero)aralkyl, cis-C(Q):CHT; Q = H, alk(en)(yn)yl; T = (un)substituted (hetero)aryl, substituted cycloalkyl; L = H, U; M = O, CHU; U = H, alk(en)yl, cycloalk(en)ylalk(en)yl, (hetero)aralk(en)yl, (hetero)aryl; J = H, alkyl, CH2Ph; K = alkyl, CH2Ph, cyclohexylmethyl; or JK = atoms to form 5- to 7-membered, optionally O- or S-containing heterocycle; m = 0-3; various provisos], as well as pharmaceutical compns. comprising them, which possess a broad range of useful biol. activities. These compds. can maintain, increase, or restore sensitivity of cells to therapeutic or prophylactic agents. They can also suppress, modify, or significantly reduce an immune response, including an autoimmune response in a mammal. This invention also relates to pharmaceutical compns. comprising these compds. The compds. and pharmaceutical compns. of this invention are particularly well-suited for treatment of multi-drug resistant cells, for prevention of the development of multi-drug resistance, for use in multi-drug resistant cancer therapy, and for prevention or treatment of graft rejection and various autoimmune diseases. Over 100 I are reported, including both single and mixed diastereomers. Thus, 3-PhOC6H4CH2OH underwent oxidation to the aldehyde and reaction with Ph(CH2)3MgBr to give the racemic alc. 3-PhOC6H4CH(OH)(CH2)3Ph (II). Esterification of II with (S)-N-[(3,4,5-trimethoxyphenyl)glyoxyl]pipecolic acid (preparation given) yielded ester III as a mixture of diastereomers. In a test for reversal of multi-drug-resistance by a line of L1210 cells, selected I gave up to 18-fold increase in the antiproliferative potency of doxorubicin.

IT 159997-95-2P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of acylated amino acid esters for multi-drug resistance therapies and immune suppression.)

RN 159997-95-2 CAPLUS

CN L-Proline, 1-[oxo(3,4,5-trimethoxyphenyl)acetyl]-, 4-(3-pyridinyl)-1-[3-(3-pyridinyl)propyl]butyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L17 ANSWER 4 OF 4 CAPLUS COPYRIGHT 2007 ACS on STN

AN 1995:274880 CAPLUS

DN 122:55896

TI 1-(2-oxoacetyl)piperidine-2-carboxylic acid derivatives as multi-drug-resistant cancer cell sensitizers

IN Armistead, David M.; Saunders, Jeffrey O.; Boger, Joshua S.

PA Vertex Pharmaceuticals Inc., USA

SO PCT Int. Appl., 111 pp.
CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 4

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9407858	A1	19940414	WO 1993-US9145	19930927

W: AT, AU, BB, BG, BR, BY, CA, CH, CZ, DE, DK, ES, FI, GB, HU, JP, KP, KR, KZ, LK, LU, LV, MG, MN, MW, NL, NO, NZ, PL, PT, RO, RU, SD, SE, SK, UA, UZ, VN
RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG

NZ	314207	A	20001222	NZ 1993-314207	19930727
IL	107109	A	19990312	IL 1993-107109	19930926
AU	9351648	A	19940426	AU 1993-51648	19930927
AU	690082	B2	19980423		
EP	662958	A1	19950719	EP 1993-922748	19930927
EP	662958	B1	20021211		
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, MC, NL, PT, SE				
JP	08502256	T	19960312	JP 1994-509216	19930927
JP	3635493	B2	20050406		
HU	72046	A2	19960328	HU 1995-890	19930927
RU	2158258	C2	20001027	RU 1995-110938	19930927
CZ	287396	B6	20001115	CZ 1995-769	19930927
RO	117791	B1	20020730	RO 1995-599	19930927
AT	229506	T	20021215	AT 1993-922748	19930927
PT	662958	T	20030430	PT 1993-922748	19930927
CA	2144962	C	20030520	CA 1993-2144962	19930927
ES	2188595	T3	20030701	ES 1993-922748	19930927
SK	284129	B6	20040908	SK 1995-389	19930927
CN	1088577	A	19940629	CN 1993-118201	19930928
CN	1086386	B	20020619		
CN	1494906	A	20040512	CN 2002-2002108738	19930928
FI	9501454	A	19950327	FI 1995-1454	19950327
NO	9501162	A	19950529	NO 1995-1162	19950327
NO	305596	B1	19990628		
HK	1013992	A1	20030815	HK 1998-115242	19981223
PRAI US	1992-952299	A	19920928		
	WO 1993-US9145	W	19930927		

OS MARPAT 122:55896

GI



I



II

AB The invention relates to compds. I [A = CH2, O, NH, alkylimino; B, D = (un)substituted (hetero)aryl, alk(en)(yn)yl, cycloalk(en)ylalk(en)(yn)yl, (hetero)aralkyl, cis-C(Q):CHT; Q = H, alk(en)(yn)yl; T = (un)substituted (hetero)aryl, substituted cycloalkyl; L = H, U; M = O, CHU; U = H, alk(en)yl, cycloalk(en)ylalk(en)yl, (hetero)aralk(en)yl, (hetero)aryl; J = H, alkyl, CH2Ph; K = alkyl, CH2Ph, cyclohexylmethyl; or JK = atoms to form 5- to 7-membered, optionally O- or S-containing heterocycle; m = 0-3; various provisos], as well as pharmaceutical compns. comprising them. The compds. maintain, increase, or restore sensitivity of cells to therapeutic or prophylactic agents, and are particularly well-suited for treatment or prevention of multi-drug resistant cancer cells. Over 100 I are reported, including both single and mixed diastereomers. For example,

3-PhOC6H4CH2OH underwent oxidation to the aldehyde and reaction with Ph(CH2)3MgBr to give the racemic alc. 3-PhOC6H4CH(OH)(CH2)3Ph. Esterification of this with (S)-N-[(3,4,5-trimethoxyphenyl)glyoxyl]pipecol ic acid (preparation given) yielded the ester II as a mixture of diastereomers. In a test for reversal of multi-drug-resistance by a line of L1210 cells, selected I gave up to 18-fold increase in the antiproliferative potency of doxorubicin.

IT 159997-95-2P
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of, as sensitizer for multi-drug-resistant cancer cells)

RN 159997-95-2 CAPLUS

CN L-Proline, 1-[oxo(3,4,5-trimethoxyphenyl)acetyl]-, 4-(3-pyridinyl)-1-[3-(3-pyridinyl)propyl]butyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L23 ANSWER 16 OF 16 CAPLUS COPYRIGHT 2007 ACS on STN
AN 1997:400101 CAPLUS
DN 127:23742
TI Method, compositions and kits for increasing the oral bioavailability of pharmaceutical agents
IN Broder, Samuel; Duchin, Kenneth L.; Selim, Sami
PA Baker Norton Pharmaceuticals, Inc., USA
SO PCT Int. Appl., 136 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 5

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9715269	A2	19970501	WO 1996-IB1485	19961024
	WO 9715269	A3	19970731		
	W: AM, AT, AU, BB, BG, BR, BY, CA, CH, CN, CZ, DE, DK, EE, ES, FI, GB, GE, HU, IL, JP, KE, KG, KP, KR, KZ, LK, LR, LT, LU, LV, MD, MG, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, TJ, TT, UA, UZ, VN				
	RW: KE, LS, MW, SD, SZ, UG, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
	US 5968972	A	19991019	US 1996-608776	19960229
	US 6245805	B1	20010612	US 1996-733142	19961016
	AU 9712056	A	19970515	AU 1997-12056	19961024
	AU 698142	B2	19981022		
	EP 794794	A1	19970917	EP 1996-943268	19961024
	EP 794794	B1	20051207		
	R: AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LI, LU, MC, NL, PT, SE				
	JP 10509741	T	19980922	JP 1997-516449	19961024
	JP 3361102	B2	20030107		
	BR 9607066	A	20021210	BR 1996-7066	19961024
	RU 2217135	C2	20031127	RU 1997-112888	19961024
	PL 188281	B1	20050131	PL 1996-321791	19961024
	AT 311903	T	20051215	AT 1996-943268	19961024
	PL 192544	B1	20061130	PL 1996-368566	19961024
	ZA 9609001	A	19970617	ZA 1996-9001	19961025
	IN 1996CA01864	A	20051028	IN 1996-CA1864	19961025
	NO 9702968	A	19970723	NO 1997-2968	19970625
	NO 321091	B1	20060313		
	HK 1001960	A1	20060127	HK 1998-101042	19980211
	AU 200235584	A	20020606	AU 2002-35584	20020422
	AU 784159	B2	20060216		
PRAI	US 1995-7071P	P	19951026		
	US 1996-608776	A	19960229		
	US 1996-733142	A	19961016		
	WO 1996-IB1485	W	19961024		
	AU 1998-71300	A3	19980422		

AB A method of increasing the bioavailability upon oral administration of a pharmacol. active target agent, particularly an antitumor or antineoplastic agent which exhibits poor or inconsistent oral bioavailability (e.g., paclitaxel, docetaxel or etoposide), comprises the oral co-administration to a mammalian patient of the target agent and an oral bioavailability-enhancing agent (e.g., cyclosporin A, cyclosporin D, cyclosporin F, or ketoconazole). The oral bioavailability-enhancing agents are known to be MDR (P-glycoprotein) inhibitors. The enhancing agent may be administered orally from 0.5-24 h prior to the oral administration of one or more doses of the target agent, substantially simultaneously with the target agent, or both prior to and substantially

simultaneously with the target agent. A method of treating mammalian patients suffering from diseases responsive to target agents with poor oral bioavailability, as well as oral dosage forms containing such target agents, combination oral dosage forms containing bioavailability-enhancing agents and target agents kits containing enhancing and target agent dosage forms and dosing information for the co-administration of the same are also disclosed.

=> d bib abs 1-15

L23 ANSWER 1 OF 16 CAPLUS COPYRIGHT 2007 ACS on STN
AN 2007:86292 CAPLUS
DN 146:169222
TI Compositions of placentally-derived stem cells for the treatment of cancer
IN Ichim, Thomas E.
PA Medistem Laboratories, Inc., USA
SO PCT Int. Appl., 41pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 2007011693	A2	20070125	WO 2006-US27305	20060712
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW				
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
US 2007041954	A1	20070222	US 2006-486635	20060713
PRAI US 2005-699579P	P	20050714		

AB Disclosed are prepns. of placentally-derived stem cells and compns. useful for the treatment of cancer. Said stem cells and compns. function through inducing a "guided differentiation" program in cancer cells, thereby reducing malignancy. Further extension of the invention pertains to augmenting ability of administered cells to induce differentiation through the co-administration of known differentiation inducing agents. Within the context of this disclosure, methods for inducing host responses to cancer are also described.

L23 ANSWER 2 OF 16 CAPLUS COPYRIGHT 2007 ACS on STN
AN 2006:1099544 CAPLUS
DN 145:432182
TI Method for treating prostate conditions
IN Smith, Gary J.; Huss, Wendy J.
PA USA
SO U.S. Pat. Appl. Publ., 20pp.
CODEN: USXXCO
DT Patent
LA English
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI US 2006233809	A1	20061019	US 2006-350171	20060208

WO 2007037782 A2 20070405 WO 2006-US4523 20060208
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
PRAI US 2005-651101P P 20050208
AB The invention provides a method for inhibiting the aberrant growth of cells in a prostate tissue in an individual comprising administering to the individual an amount of an inhibitor of the Breast Cancer Resistance Protein (BCRP/ABCG2), where the amount of the BCRP inhibitor is effective to inhibit the growth of the aberrantly growing cells. The method is also useful for treating prostate tumors or benign prostatic hyperplasia/hypertrophy (BPH). Also disclosed is the phenotype for prostate stem cells as determined by immunohistochem. localization methods. The prostate stem cells are pos. for BCRP protein, neg. for androgen receptor protein, neg. for p63 protein, and neg. for synaptophysin.

L23 ANSWER 3 OF 16 CAPLUS COPYRIGHT 2007 ACS on STN
AN 2006:566785 CAPLUS
DN 145:55958
TI Method for treatment and prevention of epilepsy
IN Nedergaard, Maiken; Tian, Guo Feng
PA University of Rochester, USA
SO PCT Int. Appl., 122 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 2006062683	A2	20060615	WO 2005-US41058	20051114

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM

PRAI US 2004-627847P P 20041115
AB The invention is directed to a method of treating or preventing epileptic seizures in a subject and a method of inhibiting hypersynchronous burst activity of neurons by administering an agent which interferes with glutamate, aspartate, and/or ATP release from astrocytes. Also presented is a method of identifying agents suitable for treating or preventing epileptic seizures.

L23 ANSWER 4 OF 16 CAPLUS COPYRIGHT 2007 ACS on STN
AN 2005:426232 CAPLUS
DN 142:477356

TI Rescue agents for treating botulinum toxin intoxications
IN Li, Shengwen; Aoki, Kei Roger
PA Allergan, Inc., USA
SO U.S. Pat. Appl. Publ., 61 pp.
CODEN: USXXCO
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 2005106182	A1	20050519	US 2003-715810	20031117
	US 7172764	B2	20070206		
	AU 2004291152	A1	20050602	AU 2004-291152	20041115
	CA 2546383	A1	20050602	CA 2004-2546383	20041115
	WO 2005048949	A2	20050602	WO 2004-US38320	20041115
	WO 2005048949	A3	20060323		
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	EP 1684799	A2	20060802	EP 2004-816954	20041115
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, PL, SK, HR, IS, YU				
PRAI	US 2003-715810	A	20031117		
	WO 2004-US38320	W	20041115		

AB The present invention relates to rescue agents for use in the treatments of toxin intoxication-for example botulinum intoxication, which can result from food poisoning, an act of bioterrorism, or from accidental overdose in the course of treatment. In some embodiments, the rescue agents comprise at least one of an inactive botulinum toxin and a modified nontoxic nonhemagglutinin. The present invention also provides for glycosylated active and inactive toxins and methods of using same.
RE.CNT 109 THERE ARE 109 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L23 ANSWER 5 OF 16 CAPLUS COPYRIGHT 2007 ACS on STN
AN 2005:216616 CAPLUS
DN 142:285198
TI Ultrasonic concentration of drug delivery capsules
IN Dayton, Paul; Ferrara, Katherine W.; Shortencarier, Michaelann; Bloch, Susannah
PA The Regents of the University of California, USA
SO PCT Int. Appl., 67 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2005020918	A2	20050310	WO 2004-US27931	20040827
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI,				

NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY,
TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM,
AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK,
EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE,
SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE,
SN, TD, TG

US 2005084538	A1	20050421	US 2004-928648	20040826
EP 1663109	A2	20060607	EP 2004-782415	20040827

R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, PL, SK, HR

PRAI US 2003-498405P	P	20030827	
US 2004-928648	A	20040826	
WO 2004-US27931	W	20040827	

AB Methods, compns. and apparatus for localized delivery of compds. are provided. In certain embodiments, radiation force is used to direct carriers to a target site, and addnl. radiation is used to fragment the localized carriers, releasing associate compds. Ultrasound radiation is preferred as the source for radiation force and for fragmentation. Also encompassed are embodiments in which targeting and fragmentation are combined with imaging of the treatment site. Alternate embodiments are disclosed in which compds. are locally delivered without use of carriers. Acoustically-active lipospheres (AALs) containing Sudan Black dye were produced. Mice were injected with AALs containing Sudan Black showed that there was increased deposition of the dye in the region of tissue subjected to insonation. AALs containing Sudan Black were also shown to adhere to endothelial cells.

L23 ANSWER 6 OF 16 CAPLUS COPYRIGHT 2007 ACS on STN
AN 2005:136528 CAPLUS
DN 142:212405
TI Means and methods for treating a disease which is associated with an excess transport of hyaluronan across a lipid bilayer
IN Prehm, Peter
PA Universitaetsklinikum Muenster, Germany
SO PCT Int. Appl., 200 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 2005013947	A2	20050217	WO 2004-EP8547	20040729
WO 2005013947	A3	20050407		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH,
CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD,
GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC,
LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI,
NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY,
TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM,
AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK,
EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE,
SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE,
SN, TD, TG

AU 2004262494	A1	20050217	AU 2004-262494	20040729
CA 2533846	A1	20050217	CA 2004-2533846	20040729
EP 1660072	A2	20060531	EP 2004-741329	20040729

R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
IE, SI, FI, RO, CY, TR, BG, CZ, EE, HU, PL, SK

PRAI EP 2003-16615	A	20030729	
EP 2003-17374	A	20030731	

EP 2003-25102 A 20031031
EP 2004-12369 A 20040525
WO 2004-EP8547 W 20040729

AB The present invention relates to the use of at least one inhibitor of at least one ABC-transporter capable of transporting hyaluronan across a lipid bilayer, for the preparation of a pharmaceutical composition for the treatment of a disease which is associated with an excess transport of hyaluronan across a lipid bilayer, e.g. arthritis. Furthermore, the present invention relates to a method for screening a compound which is suitable for the treatment of a disease which is associated with an excess transport of hyaluronan across a lipid bilayer, e.g. arthritis. The present invention also relates to a method for screening a compound which reduces the transport of hyaluronan mediated by (an) ABC-transporter(s). Furthermore, the present invention relates to a method for identifying a subject at risk for a disease which is associated with an excess transport of hyaluronan across a lipid bilayer, e.g. arthritis as well as to a method of screening for a compound which is suitable for the treatment of a disease which is associated with an excess transport of hyaluronan across a lipid bilayer, e.g. arthritis in a subject. In addition, the present invention relates to a method of preventing, ameliorating and/or treating the symptoms of a disease which is associated with an excess transport of hyaluronan across a lipid bilayer, e.g. arthritis in a subject.

L23 ANSWER 7 OF 16 CAPLUS COPYRIGHT 2007 ACS on STN
AN 2005:76266 CAPLUS
DN 142:148758
TI Augmenting the activity of antibacterial agents using efflux pump inhibitors
IN Grossman, Trudy Hope
PA Vertex Pharmaceuticals Incorporated, USA
SO PCT Int. Appl., 139 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 2005007162	A1	20050127	WO 2004-US21973	20040709
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
US 2005090482	A1	20050428	US 2004-887719	20040709
PRAI US 2003-486041P	P	20030710		
US 2003-486046P	P	20030710		
US 2003-486102P	P	20030710		
US 2003-486235P	P	20030710		

OS MARPAT 142:148758

AB The present invention relates to compds. that potentiate the activity of antibacterials. The present invention also relates to compns. useful in treating bacterial infection in mammals, and methods therewith. The present invention also relates to a method of inhibiting bacterial efflux of an antibiotic, thereby increasing the efficacy of the antibiotic.

RE.CNT 11 THERE ARE 11 CITED REFERENCES AVAILABLE FOR THIS RECORD

ALL CITATIONS AVAILABLE IN THE RE FORMAT

L23 ANSWER 8 OF 16 CAPLUS COPYRIGHT 2007 ACS on STN
AN 2004:1036851 CAPLUS
DN 142:696
TI Synergistic treatment of cancer using immunomers in conjunction with chemotherapeutic agents
IN Kandimalla, Ekambar R.; Agrawal, Sudhir; Wang, Daqin
PA Hybridon, Inc., USA
SO PCT Int. Appl., 106 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2004103301	A2	20041202	WO 2004-US15313	20040514
	WO 2004103301	A3	20051103		
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	AU 2004241093	A1	20041202	AU 2004-241093	20040514
	CA 2526212	A1	20041202	CA 2004-2526212	20040514
	US 2005009773	A1	20050113	US 2004-846167	20040514
	EP 1628531	A2	20060301	EP 2004-752345	20040514
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, PL, SK, HR				
	JP 2006528697	T	20061221	JP 2006-533117	20040514
PRAI	US 2003-471247P	P	20030516		
	WO 2004-US15313	W	20040514		

OS MARPAT 142:696
AB The invention discloses the therapeutic use of immunostimulatory oligonucleotides and/or immunomers in combination with chemotherapeutic agents to provide a synergistic therapeutic effect.

L23 ANSWER 9 OF 16 CAPLUS COPYRIGHT 2007 ACS on STN
AN 2003:202416 CAPLUS
DN 138:226752
TI Vaginal delivery of drugs and inhibitors of membrane efflux systems for cancer therapy
IN Pauletti, Giovanni M.; Liu, James H.; Benet, Leslie Z.; Ritschel, Wolfgang A.
PA UMD, Inc., USA
SO PCT Int. Appl., 61 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 12

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2003020210	A2	20030313	WO 2002-US27027	20020821
	WO 2003020210	A3	20031120		
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH,				

GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZM, ZW
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

	AU 765269	B2	20030911	AU 2001-54192	20010703
	CA 2457526	A1	20030313	CA 2002-2457526	20020821
	EP 1427366	A2	20040616	EP 2002-766096	20020821
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, SK				
	JP 2005507874	T	20050324	JP 2003-524524	20020821
PRAI	US 2001-315877P	P	20010829		
	AU 1998-76976	A3	19980610		
	WO 2002-US27027	W	20020821		

AB Devices, methods, and compns. for cancer therapy by administration of chemotherapeutic agents and/or inhibitors of membrane efflux systems to the vagina for topical and systemic tumor targets are disclosed. Vaginal suppositories were prepared from verapamil-HCl 0.75, HPMC 600, and Transcutol 600 mg, Suppocire AS2 4.8 (for 8 suppositories).

L23 ANSWER 10 OF 16 CAPLUS COPYRIGHT 2007 ACS on STN
AN 2002:241334 CAPLUS
DN 136:257275
TI Method and composition for modulating amyloidosis
IN Reiner, Peter B.; Lam, Fred Chiu-Lai
PA Can.
SO U.S. Pat. Appl. Publ., 38 pp., Cont.-in-part of U.S. Ser. No. 67,523, abandoned.
CODEN: USXXCO
DT Patent
LA English
FAN.CNT 3

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 2002037843	A1	20020328	US 1998-177413	19981023
	US 6514686	B2	20030204		
	CA 2348019	A1	20000504	CA 1999-2348019	19991014
	WO 2000024390	A1	20000504	WO 1999-US23885	19991014
	W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
	EP 1123090	A1	20010816	EP 1999-954894	19991014
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
	JP 2002528411	T	20020903	JP 2000-578000	19991014
	AU 762593	B2	20030626	AU 2000-11128	19991014
	US 6660725	B1	20031209	US 2000-643511	20000822
PRAI	US 1997-847616	B2	19970428		
	US 1998-67523	B2	19980428		
	US 1998-177413	A	19981023		
	WO 1999-US23885	W	19991014		

AB Methods for modulating amyloid deposition in a subject are described. An effective amount of at least one ATP binding cassette (ABC) transporter

blocker is administered to a subject, such that modulation of amyloid deposition occurs. Methods also include administering and effective amount of at least one ABC transporter blocker, or a pharmaceutically acceptable salt thereof, to a subject such that a disease state associated with amyloidosis is treated. Packaged pharmaceutical compns. for treating amyloidosis are described. The package includes a container for holding an effective amount of a pharmaceutical composition and instructions for using the pharmaceutical composition for treatment of amyloidosis. The pharmaceutical composition includes at least one ABC blocker for modulating amyloid deposition in a subject. Methods for identifying agents which modulate amyloid deposition in a subject are also described. An effective amount of at least one ATP binding cassette (ABC) transporter blocker is administered to an organism, such that modulation of amyloid deposition occurs.

L23 ANSWER 11 OF 16 CAPLUS COPYRIGHT 2007 ACS on STN
AN 2001:935435 CAPLUS
DN 136:84677
TI Methods for enhancing antibody-induced cell lysis and treating cancer
IN Weiner, George; Hartmann, Gunther
PA University of Iowa Research Foundation, USA
SO PCT Int. Appl., 312 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2001097843	A2	20011227	WO 2001-US20154	20010622
	WO 2001097843	A3	20030123		
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
	CA 2410371	A1	20011227	CA 2001-2410371	20010622
	AU 2001070134	A5	20020102	AU 2001-70134	20010622
	US 2003026801	A1	20030206	US 2001-888326	20010622
	EP 1296714	A2	20030402	EP 2001-948684	20010622
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
	JP 2003535907	T	20031202	JP 2002-503327	20010622
	AU 2006216542	A1	20061012	AU 2006-216542	20060915
PRAI	US 2000-213346P	P	20000622		
	AU 2001-270134	A3	20010622		
	WO 2001-US20154	W	20010622		

AB The invention relates to methods and products for treating cancer. In particular the invention relates to combinations of nucleic acids and antibodies for the treatment and prevention of cancer. The invention also relates to diagnostic methods for screening cancer cells.

L23 ANSWER 12 OF 16 CAPLUS COPYRIGHT 2007 ACS on STN
AN 2000:475560 CAPLUS
DN 133:109949
TI Pharmaceutical compositions for treatment of diseased tissues
IN Lee, Clarence C.; Lee, Feng-Min
PA USA
SO PCT Int. Appl., 26 pp.

CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 2000040269	A2	20000713	WO 2000-US191	20000105
WO 2000040269	A3	20001130		

W: AU, CA, CN, JP
RW: AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE

PRAI US 1999-114906P P 19990105

AB A method to treat diseased tissue is provided where a cytotoxic compound is administered to a patient in need of treatment in combination with an immunostimulant. Diseased cells and/or infectious microbes/viruses are killed by the cytotoxic compound in the presence of the immunostimulant. The cell components including cellular contents and cell membrane fragments are presented by the immunostimulant to the host animal as antigens to stimulate the immune responses toward other diseased cells of the same type(s), that either remain in the vicinity or reside in distant tissues or organs. The cytotoxic mol. and immunostimulant are preferably applied locally at high concns., either sequentially or, preferably, simultaneously. For example, the composition can be administered directly to a target cancer. The composition can be prepared in various forms, such as a paste, a time release molded solid shape, a solution, a mixture with emulsifier, etc. Alternatively, the cytotoxic mol. and immunostimulant are applied in sequence.

L23 ANSWER 13 OF 16 CAPLUS COPYRIGHT 2007 ACS on STN
AN 2000:290832 CAPLUS
DN 132:318003
TI Method and composition for modulating amyloidosis
IN Reiner, Peter B.; Lam, Fred Chiu-lai
PA The University of British Columbia, Can.
SO PCT Int. Appl., 86 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 3

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 2000024390	A1	20000504	WO 1999-US23885	19991014
W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
US 2002037843	A1	20020328	US 1998-177413	19981023
US 6514686	B2	20030204		
CA 2348019	A1	20000504	CA 1999-2348019	19991014
EP 1123090	A1	20010816	EP 1999-954894	19991014
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
JP 2002528411	T	20020903	JP 2000-578000	19991014
AU 762593	B2	20030626	AU 2000-11128	19991014
PRAI US 1998-177413	A2	19981023		
US 1997-847616	B2	19970428		
US 1998-67523	B2	19980428		

WO 1999-US23885 W 19991014

AB Methods for modulating amyloid deposition in a subject are described. An effective amount of at least one ATP-binding cassette (ABC) transporter blocker is administered to a subject, such that modulation of amyloid deposition occurs. Methods also include administering an effective amount of at least one ABC transporter blocker, or a pharmaceutically acceptable salt thereof, to a subject such that a disease state associated with amyloidosis is treated. Packaged pharmaceutical compns. for treating amyloidosis are described. The package includes a container for holding an effective amount of a pharmaceutical composition and instructions for using the pharmaceutical composition for treatment of amyloidosis. The pharmaceutical composition includes at least one ABC blocker for modulating amyloid deposition in a subject. Methods for identifying agents which modulate amyloid deposition in a subject are also described. An effective amount of at least one ATP binding cassette (ABC) transporter blocker is administered to an organism, such that modulation of amyloid deposition occurs.

RE.CNT 1 THERE ARE 1 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L23 ANSWER 14 OF 16 CAPLUS COPYRIGHT 2007 ACS on STN
AN 1999:795653 CAPLUS
DN 132:30816
TI Methods and compositions using P-glycoprotein inhibitors for increasing penetration of HIV protease inhibitors
IN Brouwer, Kenneth Russell; Polli, Joseph William
PA Glaxo Group Limited, UK
SO PCT Int. Appl., 22 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9964001	A2	19991216	WO 1999-EP3827	19990603
	WO 9964001	A3	20000203		
	W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
	AU 9945051	A	19991230	AU 1999-45051	19990603
	EP 1094814	A2	20010502	EP 1999-927848	19990603
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI				
PRAI	GB 1998-12189	A	19980605		
	WO 1999-EP3827	W	19990603		

AB The invention relates to methods for increasing penetration of HIV protease-inhibiting compds. into tissues expressing P-glycoprotein. Central nervous system penetration of an HIV protease inhibitor, e.g. amprenavir, is increased with administration of a P-glycoprotein inhibitor, e.g. 9,10-dihydro-5-methoxy-9-oxo-N-[4-(2-(1,2,3,4-tetrahydro-6,7-dimethoxy-2-isoquinolinyl)ethyl)phenyl]-4-5 acridinecarboxamide (GF120918).

L23 ANSWER 15 OF 16 CAPLUS COPYRIGHT 2007 ACS on STN
AN 1998:719248 CAPLUS
DN 130:510

TI Method and composition for modulating amyloidosis

IN Reiner, Peter B.; Lam, Fred Chiu-lai
PA The University of British Columbia, Can.

SO PCT Int. Appl., 67 pp.
CODEN: PIXXD2
DT Patent
LA English

FAN.CNT 3

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9848784	A2	19981105	WO 1998-US8463	19980428
	WO 9848784	A3	19990812		
	W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, GW, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
	CA 2285948	A1	19981105	CA 1998-2285948	19980428
	AU 9872603	A	19981124	AU 1998-72603	19980428
	EP 979086	A2	20000216	EP 1998-919923	19980428
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI				
	JP 2002504895	T	20020212	JP 1998-547254	19980428
PRAI	US 1997-847616	A2	19970428		
	WO 1998-US8463	W	19980428		

AB Methods for modulating amyloid deposition in a subject are described. An effective amount of at least one ATP-binding cassette (ABC) transporter blocker is administered to a subject, such that modulation of amyloid deposition occurs. Methods also include administering an effective amount of at least one ABC transporter blocker, or a pharmaceutically acceptable salt thereof, to a subject such that a disease state associated with amyloidosis is treated. Packaged pharmaceutical compns. for treating amyloidosis are described. The package includes a container for holding an effective amount of a pharmaceutical composition and instructions for using the pharmaceutical composition for treatment of amyloidosis. The pharmaceutical composition includes at least one ABC blocker for modulating amyloid deposition in a subject. Methods for identifying agents which modulate amyloid deposition in a subject are also described. An effective amount of at least one ATP binding cassette (ABC) transporter blocker is administered to an organism, such that modulation of amyloid deposition occurs.

```
? b 411
       16apr07 15:01:58 User208650 Session D916.2
            $0.00    0.117 DialUnits File410
     $0.00  Estimated cost File410
     $0.02  TELNET
     $0.02  Estimated cost this search
     $0.54  Estimated total session cost   0.267 DialUnits
File 411:DIALINDEX(R)

DIALINDEX(R)
   (c) 2007 Dialog

*** DIALINDEX search results display in an abbreviated ***
*** format unless you enter the SET DETAIL ON command. ***
? sf medicine
>>>         138 is unauthorized
>>>1 of the specified files is not available
   You have 25 files in your file list.
   (To see banners, use SHOW FILES command)
? s neurotroph?(20n)alzheimer

Your SELECT statement is:
   s neurotroph?(20n)alzheimer

          Items   File
          -----   ----
            258     5: Biosis Previews(R)_1926-2007/Apr W1
            351    34: SciSearch(R) Cited Ref Sci_1990-2007/Apr W2
             11    35: Dissertation Abs Online_1861-2007/Mar
             44    45: EMCare_2007/Apr W2
             17    65: Inside Conferences_1993-2007/Apr 16
            243    71: ELSEVIER BIOBASE_1994-2007/Apr W3
            249    73: EMBASE_1974-2007/Apr 12
              7    98: General Sci Abs_1984-2007/Apr
             39   135: NewsRx Weekly Reports_1995-2007/Apr W2
            186   144: Pascal_1973-2007/Apr W2
             39   149: TGG Health&Wellness DB(SM)_1976-2007/Apr W1
            280   155: MEDLINE(R)_1950-2007/Apr 13
             89   156: ToxFile_1965-2007/Apr W2
             20   159: Cancerlit_1975-2002/Oct
              7   162: Global Health_1983-2007/Mar
              3   172: EMBASE Alert_2007/Apr 12
             18   266: FEDRIP_2007/Mar
              2   369: New Scientist_1994-2007/Dec W1
            367   399: CA SEARCH(R)_1967-2007/UD=14616
              1   434: SciSearch(R) Cited Ref Sci_1974-1989/Dec
              6   444: New England Journal of Med._1985-2007/Apr W1

   21 files have one or more items; file list includes 25 files.

? rf
Your last SELECT statement was:
   S NEUROTROPH?(20N)ALZHEIMER

Ref       Items   File
---       -----   ----
N1          367   399: CA SEARCH(R)_1967-2007/UD=14616
N2          351    34: SciSearch(R) Cited Ref Sci_1990-2007/Apr W2
N3          280   155: MEDLINE(R)_1950-2007/Apr 13
N4          258     5: Biosis Previews(R)_1926-2007/Apr W1
N5          249    73: EMBASE_1974-2007/Apr 12
```

```
N6           243    71: ELSEVIER BIOBASE_1994-2007/Apr W3
N7           186   144: Pascal_1973-2007/Apr W2
N8            89   156: ToxFile_1965-2007/Apr W2
N9            44    45: EMCare_2007/Apr W2
N10           39   135: NewsRx Weekly Reports_1995-2007/Apr W2
   21 files have one or more items; file list includes 25 files.

        - Enter P or PAGE for more -
? b n1-n10
       16apr07 15:02:35 User208650 Session D916.3
            $1.42    0.483 DialUnits File411
     $1.42  Estimated cost File411
     $0.26  TELNET
     $1.68  Estimated cost this search
     $2.22  Estimated total session cost   0.750 DialUnits

SYSTEM:OS  - DIALOG OneSearch
  File 399:CA SEARCH(R) 1967-2007/UD=14616
         (c) 2007 American Chemical Society
*File 399: Use is subject to the terms of your user/customer agreement.
IPCR/8 classification codes now searchable as IC=. See HELP NEWSIPCR.
  File  34:SciSearch(R) Cited Ref Sci 1990-2007/Apr W2
         (c) 2007 The Thomson Corp
  File 155:MEDLINE(R) 1950-2007/Apr 13
         (c) format only 2007 Dialog
  File   5:Biosis Previews(R) 1926-2007/Apr W1
         (c) 2007 The Thomson Corporation
*File   5: BIOSIS has been enhanced with archival data. Please see
HELP NEWS 5 for information.
  File  73:EMBASE 1974-2007/Apr 12
         (c) 2007 Elsevier B.V.
  File  71:ELSEVIER BIOBASE 1994-2007/Apr W3
         (c) 2007 Elsevier B.V.
  File 144:Pascal 1973-2007/Apr W2
         (c) 2007 INIST/CNRS
  File 156:ToxFile 1965-2007/Apr W2
         (c) format only 2007 Dialog
  File  45:EMCare 2007/Apr W2
         (c) 2007 Elsevier B.V.
  File 135:NewsRx Weekly Reports 1995-2007/Apr W2
         (c) 2007 NewsRx

      Set  Items  Description
      ---  -----  -----------
? s neurotroph?(20n)alzheimer
          126072  NEUROTROPH?
          344199  ALZHEIMER
     S1     2106  NEUROTROPH?(20N)ALZHEIMER
? rd
Processing - Examined 1000 records
      S2      966  RD  (unique items)
? s s2 and pyridin?
>>>File 399 processing for PYRIDIN? stopped at PYRIDINEMETHYLAMINEDIACETATO
             966  S2
          384638  PYRIDIN?
      S3       4  S2 AND PYRIDIN?
? t/5/1-4

 3/5/1     (Item 1 from file: 399)
DIALOG(R)File 399:CA SEARCH(R)
(c) 2007 American Chemical Society. All rts. reserv.
```

134115864 CA: 134(9)115864n PATENT
Preparation of neurotrophic tetrahydroisoquinolinecarboxylates and tetrahydrothienopyridinecarboxylates
INVENTOR(AUTHOR): Macielag, Mark; Sui, Zhihua; Walsh, Shawn; Zhao, Boyu
LOCATION: USA
ASSIGNEE: Ortho-McNeil Pharmaceutical, Inc.
PATENT: PCT International ; WO 200104090 A2 DATE: 20010118
APPLICATION: WO 2000US16072 (20000612) *US PV143098 (19990709)
PAGES: 69 pp. CODEN: PIXXD2 LANGUAGE: English
PATENT CLASSIFICATIONS:
CLASS: C07D-000/A
DESIGNATED COUNTRIES: AE; AG; AL; AM; AT; AU; AZ; BA; BB; BG; BR; BY; CA; CH; CN; CR; CU; CZ; DE; DK; DM; DZ; EE; ES; FI; GB; GD; GE; GH; GM; HR; HU; ID; IL; IN; IS; JP; KE; KG; KP; KR; KZ; LC; LK; LR; LS; LT; LU; LV; MA; MD; MG; MK; MN; MW; MX; MZ; NO; NZ; PL; PT; RO; RU; SD; SE; SG; SI; SK; SL; TJ; TM; TR; TT; TZ; UA; UG; UZ; VN; YU; ZA; ZW; AM; AZ; BY; KG; KZ; MD; RU; TJ; TM DESIGNATED REGIONAL: GH; GM; KE; LS; MW; MZ; SD; SL; SZ; TZ; UG; ZW; AT; BE; CH; CY; DE; DK; ES; FI; FR; GB; GR; IE; IT; LU; MC; NL; PT; SE; BF; BJ; CF; CG; CI; CM; GA; GN; GW; ML; MR; NE; SN; TD; TG
SECTION:
CA227017 Heterocyclic Compounds (One Hetero Atom)
CA201XXX Pharmacology
IDENTIFIERS: tetrahydroisoquinolinecarboxylate tetrahydrothienyopyridinecarboxylate prepn neurotrophic
DESCRIPTORS:
Nervous system...
amyotrophic lateral sclerosis, treatment; prepn. of neurotrophic tetrahydroisoquinoline carboxylates and tetrahydrothienopyridinecarboxylates
Nerve,disease...
diabetic neuropathy, treatment; prepn. of neurotrophic tetrahydroisoquinoline carboxylates and tetrahydrothienopyridinecarboxylates
Spinal cord...
injury, treatment; prepn. of neurotrophic tetrahydroisoquinoline carboxylates and tetrahydrothienopyridinecarboxylates
Nerve,disease...
peripheral, injury, treatment; prepn. of neurotrophic tetrahydroisoquinoline carboxylates and tetrahydrothienopyridinecarboxylates
Antiparkinsonian agents... Anti-Alzheimer's agents... Neurotrophic factors ...
prepn. of neurotrophic tetrahydroisoquinoline carboxylates and tetrahydrothienopyridinecarboxylates
Brain,disease...
stroke, treatment; prepn. of neurotrophic tetrahydroisoquinoline carboxylates and tetrahydrothienopyridinecarboxylates
Brain,disease...
trauma, treatment; prepn. of neurotrophic tetrahydroisoquinoline carboxylates and tetrahydrothienopyridinecarboxylates
Paralysis...
treatment of Bell's palsy; prepn. of neurotrophic tetrahydroisoquinoline carboxylates and tetrahydrothienopyridinecarboxylates
Multiple sclerosis...
treatment; prepn. of neurotrophic tetrahydroisoquinoline carboxylates and tetrahydrothienopyridinecarboxylates
CAS REGISTRY NUMBERS:
78183-55-8P 93449-83-3P 178205-92-0P 320578-48-1P 320578-49-2P
320578-50-5P 320578-52-7P 320578-53-8P 320578-58-3P 320578-59-4P
320578-61-8P 320578-62-9P 320578-64-1P 320578-65-2P 320578-67-4P
320578-68-5P 320578-70-9P 320578-71-0P 320578-72-1P 320578-75-4P

320578-76-5P 320578-77-6P 320578-78-7P 320578-80-1P intermediate; prepn. of neurotrophic tetrahydroisoquinoline carboxylates and tetrahydrothienopyridinecarboxylates
320578-51-6P 320578-54-9P 320578-55-0P 320578-56-1P 320578-57-2P 320578-60-7P 320578-63-0P 320578-66-3P 320578-69-6P 320578-73-2P 320578-74-3P 320578-79-8P prepn. of neurotrophic tetrahydroisoquinoline carboxylates and tetrahydrothienopyridinecarboxylates
931-51-1 1124-63-6 1609-86-5 1939-99-7 2859-67-8 3685-48-1 4075-59-6 5781-53-3 20017-67-8 28276-08-6 52244-70-9 74163-81-8 88755-16-2 128502-56-7 starting material; prepn. of neurotrophic tetrahydroisoquinoline carboxylates and tetrahydrothienopyridinecarboxylates

3/5/2 (Item 2 from file: 399)
DIALOG(R)File 399:CA SEARCH(R)

133120320 CA: 133(9)120320r PATENT
Preparation of furopyridines and related compounds with neurotrophic activity.
INVENTOR(AUTHOR): Peters, Dan; Gronborg, Mette; Moller, Arne
LOCATION: Den.
ASSIGNEE: Neurosearch A/S
PATENT: PCT International ; WO 200043397 A1 DATE: 20000727
APPLICATION: WO 2000DK12 (20000113) *DK 9961 (19990119)
PAGES: 33 pp. CODEN: PIXXD2 LANGUAGE: English
PATENT CLASSIFICATIONS:
CLASS: C07D-491/048A; A61K-031/4355B; A61P-025/00B
DESIGNATED COUNTRIES: AE; AL; AM; AT; AU; AZ; BA; BB; BG; BR; BY; CA; CH; CN; CR; CU; CZ; DE; DK; DM; EE; ES; FI; GB; GD; GE; GH; GM; HR; HU; ID; IL; IN; IS; JP; KE; KG; KP; KR; KZ; LC; LK; LR; LS; LT; LU; LV; MA; MD; MG; MK; MN; MW; MX; NO; NZ; PL; PT; RO; RU; SD; SE; SG; SI; SK; SL; TJ; TM; TR; TT; TZ; UA; UG; US; UZ; VN; YU; ZA; ZW; AM; AZ; BY; KG; KZ; MD; RU; TJ; TM
DESIGNATED REGIONAL: GH; GM; KE; LS; MW; SD; SL; SZ; TZ; UG; ZW; AT; BE; CH; CY; DE; DK; ES; FI; FR; GB; GR; IE; IT; LU; MC; NL; PT; SE; BF; BJ; CF; CG; CI; CM; GA; GN; GW; ML; MR; NE; SN; TD; TG
SECTION:
CA228002 Heterocyclic Compounds (More Than One Hetero Atom)
CA201XXX Pharmacology
IDENTIFIERS: furopyridine prepn neurotrophic agent, neurodegeneration treatment furopyridine, traumatic lesion nervous system treatment furopyridine
DESCRIPTORS:
Nervous system...
amyotrophic lateral sclerosis, treatment; prepn. of furopyridines and related compds. with neurotrophic activity
Nerve...
degeneration, treatment; prepn. of furopyridines and related compds. with neurotrophic activity
Mental disorder...
dementia, treatment; prepn. of furopyridines and related compds. with neurotrophic activity
Nervous system...
Huntington's chorea, treatment; prepn. of furopyridines and related compds. with neurotrophic activity
Brain,disease...
ischemia, treatment; prepn. of furopyridines and related compds. with neurotrophic activity
Nerve,disease...
neuropathy, treatment; prepn. of furopyridines and related compds. with

neurotrophic activity
Nerve...
peripheral, treatment of traumatic lesion; prepn. of furopyridines and related compds. with neurotrophic activity
Antiparkinsonian agents... Anti-Alzheimer's agents...
prepn. of furopyridines and related compds. with neurotrophic activity
Spinal cord...
treatment of traumatic lesion; prepn. of furopyridines and related compds. with neurotrophic activity
CAS REGISTRY NUMBERS:
9061-61-4 potentiators; prepn. of furopyridines and related compds. with neurotrophic activity
99-81-0 109-65-9 177-11-7 2227-64-7 23081-86-9P 122031-10-1P 285547-51-5P 285547-52-6P 285547-53-7P 285547-54-8P 285547-55-9P 285547-56-0P 285547-58-2P 285547-59-3P 285547-60-6P 285547-61-7P 285547-62-8P 285547-63-9P 285547-64-0P prepn. of furopyridines and related compds. with neurotrophic activity

3/5/3 (Item 3 from file: 399)
DIALOG(R)File 399:CA SEARCH(R)

129067706 CA: 129(6)67706k PATENT
Preparation of 1-phenylalkyl-1,2,3,6-tetrahydropyridines for treating Alzheimer's disease
INVENTOR(AUTHOR): Baroni, Marco; Cardamone, Rosanna; Fournier, Jacqueline ; Guzzi, Umberto
LOCATION: Fr.
ASSIGNEE: Sanofi; Baroni, Marco; Cardamone, Rosanna; Fournier, Jacqueline ; Guzzi, Umberto
PATENT: PCT International ; WO 9825903 A1 DATE: 19980618
APPLICATION: WO 97FR2286 (19971212) *FR 9615335 (19961213)
PAGES: 29 pp. CODEN: PIXXD2 LANGUAGE: French
PATENT CLASSIFICATIONS:
CLASS: C07D-211/70A; C07D-401/04B; A61K-031/445B
DESIGNATED COUNTRIES: AL; AM; AT; AU; AZ; BA; BB; BG; BR; BY; CA; CH; CN; CU; CZ; DE; DK; EE; ES; FI; GB; GE; GH; GM; GW; HU; ID; IL; IS; JP; KE; KG; KP; KR; KZ; LC; LK; LR; LS; LT; LU; LV; MD; MG; MK; MN; MW; MX; NO; NZ; PL; PT; RO; RU; SD; SE; SG; SI; SK; SL; TJ; TM; TR; TT; UA; UG; US; UZ; VN; YU; ZW; AM; AZ; BY; KG; KZ; MD; RU; TJ; TM DESIGNATED REGIONAL: GH; GM; KE; LS ; MW; SD; SZ; UG; ZW; AT; BE; CH; DE; DK; ES; FI; FR; GB; GR; IE; IT; LU; MC; NL; PT; SE; BF; BJ; CF; CG; CI; CM; GA; GN; ML; MR; NE; SN; TD; TG
SECTION:
CA227016 Heterocyclic Compounds (One Hetero Atom)
CA201XXX Pharmacology
CA263XXX Pharmaceuticals
IDENTIFIERS: phenylalkyltetrahydropyridine prepn neurotrophic neuroprotecting activity, Alzheimer treatment phenylalkyltetrahydropyridine deriv, tetrahydropyridine phenylalkyl prepn neurotrophic neuroprotecting activity
DESCRIPTORS:
Alzheimer's disease...
1-phenylalkyl-1,2,3,6-tetrahydropyridines with neurotrophic and neuroprotecting activity for treatment of
CAS REGISTRY NUMBERS:
135-01-3 392-83-6 598-21-0 643-79-8 1595-07-9P 2402-78-0 3612-20-2 3637-01-2 65040-68-8 103323-56-4P 188396-79-4P 188396-80-7P 188396-81-8P 208989-20-2P 208989-22-4P 208989-24-6P 208989-30-4P 208989-32-6P 208989-34-8P for prepn. of 1-phenylalkyl-1,2,3,6-tetrahydropyridine deriv.
208989-01-9P 208989-03-1P 208989-05-3P 208989-07-5P 208989-09-7P

208989-11-1P 208989-12-2P 208989-14-4P 208989-16-6P 208989-18-8P
prepn. of 1-phenylalkyl-1,2,3,6-tetrahydropyridines for treating Alzheimer's disease

3/5/4 (Item 1 from file: 34)
DIALOG(R)File 34:SciSearch(R) Cited Ref Sci

09964173 Genuine Article#: 469WL Number of References: 206
Title: Metabotropic glutamate receptor subtypes as targets for neuroprotective drugs
Author(s): Bruno V; Battaglia G; Copani A; D'Onofrio M; Di Iorio P; De Blasi A; Melchiorri D; Flor PJ; Nicoletti F (REPRINT)
Corporate Source: Univ Roma La Sapienza,Dept Human Physiol & Pharmacol,Piazzale Aldo Moro 5/I-00185 Rome//Italy/ (REPRINT); Univ Roma La Sapienza,Dept Human Physiol & Pharmacol,I-00185 Rome//Italy/; INM Neuromed,Pozzilli//Italy/; Univ Catania,Dept Pharmaceut Sci,Catania//Italy/; Univ Chieti,Dept Biomed Sci,Chieti//Italy/; Novartis Pharma AG,Nervous Syst Res,Basel//Switzerland/
Journal: JOURNAL OF CEREBRAL BLOOD FLOW AND METABOLISM, 2001, V21, N9 (SEP), P1013-1033
ISSN: 0271-678X Publication date: 20010900
Publisher: LIPPINCOTT WILLIAMS & WILKINS, 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
Language: English Document Type: REVIEW
Geographic Location: Italy; Switzerland
Journal Subject Category: ENDOCRINOLOGY & METABOLISM; HEMATOLOGY; NEUROSCIENCES
Abstract: Metabotropic glutamate (mGlu) receptors have been considered as potential targets for neuroprotective drugs. but the lack of specific drugs has limited the development of neuroprotective strategies in experimental models of acute or chronic central nervous system (CNS) disorders. The advent of potent and centrally available subtype-selective ligands has overcome this limitation, leading to an extensive investigation of the role of mGlu receptor subtypes in neurodegeneration during the last 2 years. Examples of these drugs are the noncompetitive mGlu1 receptor antagonists, CPCCOEt and BAY-36-7620; the noncompetitive mGlu5 receptor antagonists, 2-methyl-6-(phenylethynyl)pyridine, SIB-1893, and SIB-1757; and the potent mGlu2/3 receptor agonists, LY354740 and LY379268. Pharmacologic blockade of mGlu I or mGlu5 receptors or pharmacologic activation of mGlu2/3 or mGlu4/7/8 receptors produces neuroprotection in a variety of in vitro or in vivo models. MGlu1 receptor antagonists are promising drugs for the treatment of brain ischemia or for the prophylaxis of neuronal damage induced by synaptic hyperactivity. MGlu5 receptor antagonists may limit neuronal damage induced by a hyperactivity of N-methyl-d-aspartate (NMDA) receptors, because mGlu5 and NMDA receptors are physically and functionally connected in neuronal membranes. A series of observations suggest a potential application of mGlu5 receptor antagonists in chronic neurodegenerative disorders, such as amyotrophic lateral sclerosis and Alzheimer disease. MGlu2/3 receptor agonists inhibit glutamate release, but also promote the synthesis and release of neurotrophic factors in astrocytes. These drugs may therefore have a broad application as neuroprotective agents in a variety of CNS disorders. Finally, mGlu4/7/8 receptor agonists potently inhibit glutamate release and have a potential application in seizure disorders. The advantage of all these drugs with respect to NMDA or AMPA receptor agonists derives from the evidence that mGlu receptors do not "mediate," but rather "modulate" excitatory synaptic transmission. Therefore. it can be expected that mGlu receptor ligands are devoid of the undesirable

effects resulting from the inhibition of excitatory synaptic transmission, such as sedation or an impairment of learning and memory.

Descriptors--Author Keywords: mGlu receptors ; neuroprotection ; subtype-selective ligands

Identifiers--KeyWord Plus(R): GROWTH-FACTOR-BETA; CEREBELLAR GRANULE CELLS; EXCITOTOXIC NEURONAL DEATH; RAT HIPPOCAMPAL SLICES; CULTURED CORTICAL-NEURONS; ISCHEMIC BRAIN INJURY; AMINO-ACID RECEPTORS; PROTEIN-KINASE-C; GROUP-III MGLUR; GROUP-I MGLURS